Not sure if this got answered for you, yet. My wife was recently diagnosed with Stage IV non-operable Pancreatic Cancer and we are awaiting her Tempus tumor analysis results. This is a trial I would look into if you or a loved one have a confirmed KRAS g12d mutation. This is one of the first RAS(ON) inhibitor drugs that is not localized to g12c - the compound is RMC-6236 from Revolution Medicines. The Phase III final protocol is being reviewed by FDA and the company is looking to start enrolling the trial by the end of 2024 - the results in the Phase I/Ib look very promising.

I can't post it because my account is new, but there is a link to the presentation to investors on the proposed Phase III that was just held yesterday, 7/15/24 at the Revolution Medicines website on the "Events & Presentations" tab.